Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Nigdelis, Meletios P.; Bitterlich, Annick; Parvanta, Mariam et al.
ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective StudyCANCER MEDICINE. Bd. 14. H. 16. 2025
Weimer, Johannes Matthias; Sprengart, Franziska Marietta; Vieth, Thomas et al.
Simulator training in focus assessed transthoracic echocardiography (FATE) for undergraduate medical students: results from the FateSim randomized controlled trialBMC MEDICAL EDUCATION. Bd. 25. H. 1. 2025
Schott, Sebastian; Klamminger, Gilbert Georg; Hasenburg, Annette et al.
Solitary Splenic Metastasis In Endometrial Cancer-A Systematic Review And Case PresentationINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 35. H. 2. 2025 S. 93-94
Hasenburg, Annette; Pruetting, Jens
Sustainability in gynecology-From the necessity to the chanceGYNAKOLOGIE. Bd. 58. H. 6. 2025 S. 345-346
Lukac, Stefan; Schueler-Toprak, Susanne; Hasenburg, Annette et al.
Sustainability in hospitals-What can we do?GYNAKOLOGIE. Bd. 58. H. 6. 2025 S. 373-380
Schmidt, M
Systemtherapie des HER2-low fortgeschrittenen MammakarzinomsLeading Opinions Gynäkologie & Geburtshilfe. Bd. 1/2025. 2025 S. 6-7
Mustafa, Al-Hassan M.; Petrosino, Giuseppe; Fischer, Marten A. et al.
The deacetylases HDAC1/HDAC2 control JAK2<SUP>V617F</SUP>-STAT signaling through the ubiquitin ligase SIAH2SIGNAL TRANSDUCTION AND TARGETED THERAPY. Bd. 10. H. 1. 2025
Strampfer, Lisa; Ellebrecht, Nils; Hasenburg, Annette et al.
The financial burden of fertility preservation: does the german cryo-guideline provide relief for oncology patients?PRAVENTION UND GESUNDHEITSFORDERUNG. 2025
Schwab, Roxana; Evangelos, Papanikolaou; Boutas, Ioannis et al.
The Role Of Prehabilitation In ERAS For Gynecologic Oncology In GermanyINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 35. H. 2. 2025 S. 52-52
Janni, Wolfgang; Fehm, Tanja; Mueller, Volkmar et al.
Treatment de-escalation by omission of chemotherapy & the effect of adding the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer- second interim efficacy analysis of the randomized DETECT V trialCLINICAL CANCER RESEARCH. Bd. 31. H. 12. 2025 S. P20728-P20728